HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RIFM publishes safety assessment

This article was originally published in The Rose Sheet

Executive Summary

Based on opinion of an independent expert panel, "there are no safety concerns regarding unsaturated branched chain alcohols under the present declared levels of use and exposure" in fragrance industry, says Research Institute for Fragrance Materials, the scientific arm of the International Fragrance Association. Published online, report finds that use of such materials in concentrations of 2% to 30% has been linked to no evidence or only minimal evidence of skin irritation in humans, and the ingredients will not induce sensitization though they could elicit a reaction in individuals who are already sensitized. Experts determine there is no evidence of phototoxicity, acute toxicity, systemic toxicity (after repeated application), developmental toxicity, genotoxicity or carcinogenicity associated with the substances. Like the Cosmetic Ingredient Review Expert Panel, RIFM's team organizes ingredients together based on structural similarities, "enabling consistency in predicting metabolism and toxicity and conserv[ing] resources by reducing duplicate testing" (1"The Rose Sheet" Sept. 6, 2010)

You may also be interested in...



CIR To Re-Review Sunscreen Agents Retinyl Palmitate, Oxybenzone In 2011

In light of rekindled controversy, the Cosmetic Ingredient Review Expert Panel plans to consider new safety data for sunscreen ingredients retinyl palmitate and benzophenone-3 (oxybenzone) in 2011

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel